Overcome the Translational Challenges of Developing mRNA, DNA & Viral Vector-Based Vaccines for Infectious Diseases
It has been a landmark year for gene-based vaccines once again, with the development of the first mRNA COVID-19 booster doses, approval of the world’s first DNA-based vaccine for human use, and the continued clinical development of viral vector-based vaccines.
Attend this event to:
Reunite with the vaccine community to foster new relationships, collaborations, and take advantage of those all-important face-to-face networking connections
No matter what stage of vaccine development, whether its early discovery and pipeline evaluation or clinical development and IND-filing, gain access to content that’s right for you to ensure you remain competitive within the rapidly growing genetic vaccine market
Content Beyond COVID-19
With industry rapidly expanding mRNA, DNA, and viral vector-based technology beyond COVID-19 to other infectious diseases, gain access to novel and unpublished case studies and discover how newer platforms such as srRNA and AAV vectors hold great promise for previously unmet infections.
Agenda at a Glance
| Conference Day One
Wednesday, May 25
Future Directions & Adapting to COVID-19
| Conference Day Two
Thursday, May 26
Developing Vaccines at Pandemic Speed & Clinical Challenges of COVID-19